Thursday, June 20, 2013

Lutein and Zeaxanthin Slow Progression of AMD, Confirms New NEI Study

“National Eye Institute Deputy Clinical Director Emily Chew, M.D., Ph.D., presented the results from the second Age-Related Eye Disease Study (AREDS2) at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in May. Her presentation expanded upon the results published in the Journal of the American Medical Association (JAMA),” notes a news post from the AOA (American Optometric Assn.). “The primary analysis of the study tested whether adding FloraGLO Lutein and Optisharp Zeaxanthin, DHA + EPA, or a combination of the two to the AREDS formulation reduced the risk of progression to advanced age-related macular degeneration (AMD) by an additional 25 percent as compared to study subjects taking the original AREDS supplement, which was the study control arm. The data did not demonstrate a significant reduction in progression to advanced AMD in any of the three treatment arms as compared to the control group.” Read more.

No comments:

Post a Comment